Mainz Biomed B.V. (MYNZ)
4.56
-0.02 (-0.44%)
At close: Mar 24, 2025, 3:59 PM
4.57
0.32%
After-hours: Mar 24, 2025, 07:55 PM EDT
-0.44% (1D)
| Bid | 4.51 |
| Market Cap | 10.13M |
| Revenue (ttm) | 2.92M |
| Net Income (ttm) | -64.44M |
| EPS (ttm) | -44.4 |
| PE Ratio (ttm) | -0.1 |
| Forward PE | -0.56 |
| Analyst | Hold |
| Ask | 4.64 |
| Volume | 59,423 |
| Avg. Volume (20D) | 213,243 |
| Open | 4.80 |
| Previous Close | 4.58 |
| Day's Range | 4.49 - 4.72 |
| 52-Week Range | 0.18 - 8.20 |
| Beta | 0.34 |
About MYNZ
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Nov 5, 2021
Employees 65
Stock Exchange NASDAQ
Ticker Symbol MYNZ
Website https://mainzbiomed.com
Analyst Forecast
According to 3 analyst ratings, the average rating for MYNZ stock is "Hold." The 12-month stock price forecast is $14, which is an increase of 207.02% from the latest price.
Stock Forecasts1 month ago
+11.28%
Mainz Biomed shares are trading higher after the c...
Unlock content with
Pro Subscription
3 months ago
+26.19%
Mainz Biomed shares are trading higher after the company announced it formed an agreement with Quest Diagnostics to support the commercialization of its next-gen screening test for colorectal cancer.
